Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TK2 | O00142 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL341619 | 0.94 | LMNA (0.59) | TK1LMNATSHRALBPKM | |
| Doxribtimine SCHEMBL6129436 | 0.89 | TK1 (0.64) | TK1LMNASMN1; SMN2TK2 | |
| Doxribtimine SCHEMBL17985772 | 0.89 | LMNA (0.54) | TK1LMNATSHRALBPKM | |
| Doxribtimine SCHEMBL9465657 | 0.88 | TK1 (0.51) | TK1LMNATSHRALBPKM | |
| Doxribtimine SCHEMBL1164058 | 0.86 | TK1 (0.53) | TK1LMNATSHRALBPKM | |
| Doxribtimine SCHEMBL8366525 | 0.86 | TK1 (0.53) | TK1LMNATSHRALBPKM | |
| Doxribtimine SCHEMBL1052084 | 0.86 | TK1 (0.52) | TK1LMNATSHRALBPKM | |
| Doxribtimine SCHEMBL3166229 | 0.86 | TK1 (0.52) | TK1LMNATSHRALBPKM | |
| Doxribtimine SCHEMBL3155784 | 0.86 | TK1 (0.52) | TK1LMNATSHRALBPKM | |
| Doxribtimine SCHEMBL28237206 | 0.85 | LMNA (0.51) | TK1LMNATSHRALBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140363432-A1 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF | GENENTECH, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| EP-1140173-B2 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF | GENENTECH INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-8287873-B2 | Vascular endothelial cell growth factor antagonists and uses thereof | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120237514-A1 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF | GENENTECH, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8007799-B2 | Vascular endothelial cell growth factor antagonists and uses thereof | GENENTECH, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7998931-B2 | Vascular endothelial cell growth factor antagonists and uses thereof | GENENTECH, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110185456-A1 | Annotatd plant genes | CHEIKH NORDINE | 2011-07-28 | — | — | US | disclosed |
| US-20100162622-A1 | NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED WITH THE PHOSPHOGLUCONATE PATHWAY | CHEIKH NORDINE | 2010-07-01 | — | — | US | disclosed |
| US-20100100987-A1 | NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED WITH THE TOCOPHEROL PATHWAY | BHAT BARKUR G | 2010-04-22 | — | — | US | disclosed |
| US-20100095400-A1 | Nucleic Acid Molecules and Other Molecules Associated with the Cytokinin Pathway | MONSANTO TECHNOLOGY LLC | 2010-04-15 | — | — | US | disclosed |
| US-5578461-A | GENETIC ENGINEERING; AMPLIFICATION | CELL GENESYS, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5552146-A | Methods and compositions relating to useful antigens of Moraxella catarrhalis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0612250-B1 | METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF MORAXELLA CATARRHALIS | UNIV TEXAS (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0584214-A4 | GENE MANIPULATION AND EXPRESSION USING GENOMIC ELEMENTS. | CELL GENESYS INC (US) | 1995-04-19 | — | — | EP | disclosed |
| EP-0612250-A1 | METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF -i(MORAXELLA CATARRHALIS). | UNIV TEXAS (US) | 1994-08-31 | — | — | EP | disclosed |
| EP-0584214-A1 | GENE MANIPULATION AND EXPRESSION USING GENOMIC ELEMENTS | CELL GENESYS, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1993003761-A1 | METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5173408-A | Culturing escherichia transformed with an expression vector encoding esterase, collecting and lysing the cells, loading the lysate onto a sulfated matrix, washing to remove nonbinding proteins and elution of esterase | CV THERAPEUTICS, INC. | 1992-12-22 | — | — | US | disclosed |
| WO-1992019255-A1 | GENE MANIPULATION AND EXPRESSION USING GENOMIC ELEMENTS | CELL GENESYS, INC. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0260149-A1 | Human prorelaxin for therapeutic use | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 1988-03-16 | — | — | EP | disclosed |